Independent peer reviewers don't count for approvals. They only see what NWBO feeds them -- never saw the REAL trial results, just the totally manipulated trial after changing the protocol, primary endpoint, comparator, even added a R/R leg after the trial was DONE!!!
FDA sure saw all the NWBO B.S. and they wouldn't even accept an application as they didn't buy the trial.
Dr. Liau, Ashcan, even the JAMA Oncology don't count for any commercial review. Just not how FDA isn't accepting the trial, so NWBO had to run to another country to try to salvage their future. And now look -- years of review without an approval. Let's see what happens. Even approval in UK is going to be pretty poor revenue potential based on the other personalized oncology treatment market. Oncology market in UK is less that 10% of the U.S.
Market Data 
Markets 
AI
